Member of the Board since 2017 and Chairman since July 2018.
Lars Rebien Sørensen was born in 1954 and is a Danish national. He received an MSc in Forestry from the Copenhagen Royal Veterinary and Agricultural University in 1981 and a BSc in International Economics from Copenhagen Business School in 1983.
Lars Rebien Sørensen has over 34 years of general management experience in the pharmaceutical industry. He joined the Novozymes A/S (then Novo Nordisk A/S, Enzymes Division) marketing team in 1982. Over the years he held various global positions across the Middle East and the United States. In 1994, he was appointed a member of the corporate
management team and assumed responsibility for the Novozymes A/S healthcare business. In November 2000 he became President and CEO of Novo Nordisk A/S, a position he held until December 2016.
In 2007, Lars Rebien Sørensen became an adjunct professor at the University of Copenhagen’s School of Life Sciences and in 2018 Lars Rebien Sørensen also became adjunct professor at the Center for Corporate Governance at CBS.
In addition to the role as Chairman of the Novo Holdings A/S Board, Lars Rebien Sørensen currently serves as the Chairman of the Novo Nordisk Foundation Board as well as Chairman of the Advisory Board of Axcel Management A/S. He is furthermore a Board member for Thermo Fischer Scientific Inc. based in the United States, Essity AB based in Sweden and Jungbunzlauer Suisse AG based in Switzerland.